Welcome to our dedicated page for SAB BIOTHERAPEUTICS SEC filings (Ticker: SABSW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SAB Biotherapeutics filings document a clinical-stage biopharmaceutical issuer focused on SAB-142 and human immunoglobulin G therapies for autoimmune disease. Recent Form 8-K disclosures cover Regulation FD clinical presentations for the SAB-142 HUMAN trial, other clinical data announcements, and a manufacturing services agreement for clinical and commercial supply of SAB-142.
The company’s proxy materials describe annual meeting matters, director elections, board governance, stockholder voting procedures, and executive-compensation disclosures. Its SEC record also identifies capital-structure items including common stock and warrants exercisable for common stock, along with risk and forward-looking disclosure tied to clinical development, regulatory approval, manufacturing, and financing needs.
SAB Biotherapeutics is offering shares of common stock and pre-funded warrants in a shelf-based public offering. The prospectus supplement describes an offering of common stock and, in lieu of shares, pre-funded warrants exercisable for one share at an exercise price of $0.0001 per share. The company’s common stock trades on The Nasdaq Capital Market under the symbol SABS, and it reported 47,609,899 shares outstanding as of December 31, 2025. The prospectus references proceeds, underwriting arrangements, a 30-day option for additional shares, and customary underwriting terms; specific offering amounts and pricing are presented only in completed prospectus pages. The supplement also summarizes business and clinical developments: SAB-142 is the lead clinical candidate, the company received an IND clearance in May 2024, announced positive Phase 1 topline data across multiple dates including additional Phase 1 data on March 10, 2026, and is advancing SAB-142 into a Phase 2b SAFEGUARD study after a Type B meeting with the FDA on May 29, 2025.
SAB Biotherapeutics is offering shares of common stock and pre-funded warrants in a shelf-based public offering. The prospectus supplement describes an offering of common stock and, in lieu of shares, pre-funded warrants exercisable for one share at an exercise price of $0.0001 per share. The company’s common stock trades on The Nasdaq Capital Market under the symbol SABS, and it reported 47,609,899 shares outstanding as of December 31, 2025. The prospectus references proceeds, underwriting arrangements, a 30-day option for additional shares, and customary underwriting terms; specific offering amounts and pricing are presented only in completed prospectus pages. The supplement also summarizes business and clinical developments: SAB-142 is the lead clinical candidate, the company received an IND clearance in May 2024, announced positive Phase 1 topline data across multiple dates including additional Phase 1 data on March 10, 2026, and is advancing SAB-142 into a Phase 2b SAFEGUARD study after a Type B meeting with the FDA on May 29, 2025.
SAB Biotherapeutics (SAB BIO) reported additional Phase 1 data for its lead Type 1 diabetes therapy SAB-142. In a small cohort of six adults with established Stage 3 T1D, four participants receiving SAB-142 at 2.5 mg/kg showed preserved or increased C-peptide levels at Day 120, while the single placebo completer showed a decline consistent with expected disease progression.
The company highlights biomarker evidence of T‑cell exhaustion supporting the drug’s intended mechanism and notes a previously established Phase 1 safety profile without serum sickness and with transient, reversible lymphopenia. These results supported advancing SAB-142 into the global registrational Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 T1D patients, with topline data planned for the second half of 2027.
SAB Biotherapeutics (SAB BIO) reported additional Phase 1 data for its lead Type 1 diabetes therapy SAB-142. In a small cohort of six adults with established Stage 3 T1D, four participants receiving SAB-142 at 2.5 mg/kg showed preserved or increased C-peptide levels at Day 120, while the single placebo completer showed a decline consistent with expected disease progression.
The company highlights biomarker evidence of T‑cell exhaustion supporting the drug’s intended mechanism and notes a previously established Phase 1 safety profile without serum sickness and with transient, reversible lymphopenia. These results supported advancing SAB-142 into the global registrational Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 T1D patients, with topline data planned for the second half of 2027.
SAB Biotherapeutics is a clinical-stage company developing fully human, multi-specific immunoglobulin therapies, led by SAB-142 for autoimmune type 1 diabetes. SAB-142 advanced from positive Phase 1 results into a registrational Phase 2b SAFEGUARD trial in adults, adolescents and children with new-onset Stage 3 T1D.
For 2025, revenue fell to $0 from $1.3 million in 2024 following termination of a government contract, while research and development expenses rose to $34.4 million and general and administrative expenses increased to $14.6 million as the company expanded clinical and platform work.
SAB reported net income of $13.3 million in 2025 versus a $34.1 million net loss in 2024, driven mainly by a $62.8 million non-cash gain from changes in fair value of warrant liabilities and a $61.0 million total non-operating income line.
Liquidity strengthened significantly: cash, cash equivalents and investments reached $143.5 million at year-end 2025, supported by approximately $175 million of gross proceeds from a Series B preferred stock and warrant offering, and a new Form S-3 shelf for up to $300 million, including a $75 million at-the-market program with UBS.
SAB Biotherapeutics is a clinical-stage company developing fully human, multi-specific immunoglobulin therapies, led by SAB-142 for autoimmune type 1 diabetes. SAB-142 advanced from positive Phase 1 results into a registrational Phase 2b SAFEGUARD trial in adults, adolescents and children with new-onset Stage 3 T1D.
For 2025, revenue fell to $0 from $1.3 million in 2024 following termination of a government contract, while research and development expenses rose to $34.4 million and general and administrative expenses increased to $14.6 million as the company expanded clinical and platform work.
SAB reported net income of $13.3 million in 2025 versus a $34.1 million net loss in 2024, driven mainly by a $62.8 million non-cash gain from changes in fair value of warrant liabilities and a $61.0 million total non-operating income line.
Liquidity strengthened significantly: cash, cash equivalents and investments reached $143.5 million at year-end 2025, supported by approximately $175 million of gross proceeds from a Series B preferred stock and warrant offering, and a new Form S-3 shelf for up to $300 million, including a $75 million at-the-market program with UBS.
Biotechnology Value Fund–affiliated investors reported a significant ownership position in SAB Biotherapeutics, Inc. As of the close of business on December 31, 2025, their funds and a managed account held 30,000 Tranche C warrants for Series A-3 Preferred Stock, convertible into 4,761,906 common shares.
The preferred shares convert at $6.30 per common share, based on a $1,000 per preferred share value, and the warrants are exercisable beginning November 23, 2023 for five years. Using 47,606,851 common shares outstanding as of November 10, 2025, the filing states BVF-related entities may be deemed to beneficially own up to approximately 9.1% of the class.
The structure includes a 9.99% “Maximum Percentage” cap that limits conversions so no holder, together with its affiliates and attribution parties, crosses that ownership threshold.
Biotechnology Value Fund–affiliated investors reported a significant ownership position in SAB Biotherapeutics, Inc. As of the close of business on December 31, 2025, their funds and a managed account held 30,000 Tranche C warrants for Series A-3 Preferred Stock, convertible into 4,761,906 common shares.
The preferred shares convert at $6.30 per common share, based on a $1,000 per preferred share value, and the warrants are exercisable beginning November 23, 2023 for five years. Using 47,606,851 common shares outstanding as of November 10, 2025, the filing states BVF-related entities may be deemed to beneficially own up to approximately 9.1% of the class.
The structure includes a 9.99% “Maximum Percentage” cap that limits conversions so no holder, together with its affiliates and attribution parties, crosses that ownership threshold.
RTW Investments, LP and Roderick Wong, M.D. report their ownership in SAB Biotherapeutics, Inc. on an amended Schedule 13G. They beneficially own 1,587,302 shares of common stock, equal to 3.2% of the company.
The position reflects warrants held by RTW-managed funds to purchase Series A-3 Preferred Stock that is convertible into 1,587,302 common shares. RTW Investments and Dr. Wong share voting and dispositive power over these shares, which are held by the RTW funds. They state the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of SAB Biotherapeutics.
RTW Investments, LP and Roderick Wong, M.D. report their ownership in SAB Biotherapeutics, Inc. on an amended Schedule 13G. They beneficially own 1,587,302 shares of common stock, equal to 3.2% of the company.
The position reflects warrants held by RTW-managed funds to purchase Series A-3 Preferred Stock that is convertible into 1,587,302 common shares. RTW Investments and Dr. Wong share voting and dispositive power over these shares, which are held by the RTW funds. They state the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of SAB Biotherapeutics.
SAB Biotherapeutics, Inc. is the subject of a Schedule 13G showing that Perceptive Advisors LLC, its Perceptive Life Sciences Master Fund, Ltd., and Joseph Edelman collectively report beneficial ownership of 3,471,861 shares of SAB’s common stock, representing 7.3% of the class.
The Master Fund directly holds the 3,471,861 shares, and the ownership percentage is based on 47,606,851 outstanding shares as of November 10, 2025, as disclosed in SAB’s Form 10-Q. Perceptive Advisors, as investment manager, and Mr. Edelman, as managing member, share voting and dispositive power over these shares. The filers certify the position was not acquired to change or influence control of SAB Biotherapeutics.
SAB Biotherapeutics, Inc. is the subject of a Schedule 13G showing that Perceptive Advisors LLC, its Perceptive Life Sciences Master Fund, Ltd., and Joseph Edelman collectively report beneficial ownership of 3,471,861 shares of SAB’s common stock, representing 7.3% of the class.
The Master Fund directly holds the 3,471,861 shares, and the ownership percentage is based on 47,606,851 outstanding shares as of November 10, 2025, as disclosed in SAB’s Form 10-Q. Perceptive Advisors, as investment manager, and Mr. Edelman, as managing member, share voting and dispositive power over these shares. The filers certify the position was not acquired to change or influence control of SAB Biotherapeutics.
SAB Biotherapeutics describes clinical and corporate disclosures in this amended shelf filing. The filing reports that SAB-142 showed a favorable safety profile in Phase 1 across a dose range of 0.03 mg/kg to 2.5 mg/kg, with 0% reported serum sickness and 0% reported anti-drug antibodies, supporting chronic ambulatory dosing. The company states SAB-142 demonstrated sustained immunomodulation and a multi-target mechanism of action analogous to rabbit ATG on parameters correlative to C-peptide preservation.
The prospectus reiterates extensive risk-factor topics and lists permitted methods for secondary distributions by selling stockholders. It also references recent SEC filings, including the 2024 annual report and quarterly and current reports filed in 2025, without providing financial results in the included excerpt.
Alexandra Kropotova, Chief Medical Officer of SAB Biotherapeutics, Inc. (ticker: SABSW), reported a routine insider transaction dated 09/19/2025. The Form 4 shows 1,977 shares of common stock were disposed through withholding to satisfy tax obligations on vested restricted stock units (RSUs). Following the transaction, she beneficially owns 45,272 shares, which include 29,340 vested shares and 15,932 RSUs that remain subject to vesting.
The filing is a standard Section 16 disclosure reflecting tax-withholding on RSU vesting rather than an open-market sale or purchase. The form was signed by Ms. Kropotova on 09/22/2025 and does not disclose any derivative transactions or other changes in ownership form.
SAB Biotherapeutics describes SAB-142 clinical and corporate disclosures in a shelf registration prospectus. The filing notes a favorable Phase 1 safety profile for SAB-142 across a dose range of 0.03mg/kg to 2.5mg/kg with 0% reported serum sickness and anti-drug antibodies, and states the candidate showed sustained immunomodulation and a mechanism of action analogous to rabbit ATG correlated with C-peptide preservation. The prospectus lists extensive risk factors and uncertainties about clinical development, enrollment, regulatory approval, funding, manufacturing, market acceptance, intellectual property and continued Nasdaq listing. It also outlines permitted methods for Selling Stockholders to distribute shares and cites recent SEC filings and the Form 8-A description of common stock and warrants.
SAB Biotherapeutics, Inc. solicits shareholder approval at a Special Meeting for three principal matters outlined in the proxy: approval to permit issuance in excess of 19.99% of the company’s outstanding Common Stock upon conversion of Series B Convertible Preferred Stock at less than Nasdaq’s listed "minimum price," which may be deemed a change of control under Nasdaq rules; an amendment to the 2021 Omnibus Equity Incentive Plan to increase shares available for awards by 24,180,000 to a total of 31,932,466; and to increase the Plan’s annual "evergreen" maximum from 10,000,000 shares to 73,750,000 shares. The filing discloses outstanding share counts used for ownership calculations as of August 1, 2025, showing 127,413,435 eligible voting shares, comprised of 10,411,061 Common Stock, 17,002,374 Common Stock assuming conversion of Series A-2, and 100,000,000 Common Stock assuming conversion of Series B. The proxy includes detailed beneficial ownership footnotes for officers, directors, and institutional holders, and notes specific preferred-holdings and ownership "blocker" limits (e.g., 9.99% and 4.99% blockers for certain holders).